|
Chemotherapy Updates
The pages accessed from here contain updated chemotherapy information
beginning with 2004. As new information becomes available, the tables
will be updated to reflect that new information.
It
may be tempting to compare studies directly to one another. However, there
are many reasons why this should not be done. First, studies vary in
regards to the severity of illness of patients participating. Some studies
have very ill patients with high PSA’s, while other studies have less ill
patients or patients with very low PSA’s. Because the nature of study
participants vary, we cannot tell the extent to which the effect of the
medication may be interacting with patient characteristics. Second, the
length of follow-up times may vary, the number of cycles of treatment may be
different, and a host of other factors might be influencing outcomes. If
you find an approach that looks intriguing to you, it is highly recommended
that you find and read the original journal article in its entirety so that
you can understand better whether the treatment may be applicable to your
personal situation. (B. Minton).
Every
attempt has been made to accurately summarize the many different papers and
abstracts found in the tables. Inevitably, errors occur and the reader
is always advised to seek the original source of information.
Note: The references in which the authors names are underlined have links to
the medline abstract.
Howard Hansen wrote the 2004 update and Barb Minton has written the 2005
update. The hrpca association is very grateful to her for this work.
While there are a lot of chemotherapy drugs around, not
all of them are available to prostate cancer patients. In the USA,
there are very few of them that are specifically approved for hrpca (taxotere,
emcyt, mitoxantrone) and Medicare also has restrictions.
For more information on specific chemotherapy drugs as
well as other aspects of chemotherapy, see Scott Hamilton's CARES Initiative
along with The Cleveland Clinic website at
http://www.chemocare.com/BIO/index.asp
Update of
Chemotherapy for 2004 - Part I. Taxanes and Mitoxantrone The ASCO
Annual meeting 2004 chemotherapy abstracts and published papers from 2004
are summarized here in an easy to read table format. (5 February 2005).
Most recent update 4 February 2008.
Chemotherapy Update
Tables for Taxotere(Docetaxel) and combinations starting with 2005.
Drugs combined with taxotere include: emcyt, suramin and emcyt,
Doxil(liposomal docorubicin), zometa, vinorelbine(Navelbine), g-csf,
Oblimersen sodium, Exisulind, Cisplatin, Thalidomide, Mitoxantrone, DES,
vinblastine, Xeloda(capecitabine), and thalidomide plus bevacizumab(avastin.) 19 March 2005.
Chemotherapy Update Tables for Taxol(Paclitaxel) and combinations starting
with 2005.
Combinations
include Paclitaxel and Epirubicin; Paclitaxel, Carboplatin vs
Mitoxantrone(Novantrone); Strontium, Doxorubicin, ketoconazole, Paclitaxel,
estrmustine.
19 March 2005.
Chemotherapy Update for
Studies that had prior chemotherapy (sequential treatments).
Response
to Emcyt after Prior Estrogenic Agents;
Docetaxel/emcyt after
Mitoxantrone/pednisone;
Docetaxel/Emcyt/Carboplatin
After Paclitaxel-based chemotherapy;
Docetaxel plus carboplatin After Failing Taxane-based chemotherapy.
19 March 2005.
Chemotherapy Update for
Non-classifiable combinations (unique studies)Tesmilifene and Mitoxantrone;
Tamoxifen;
Emcyt, Mitoxantrone, vinorelbine, etoposide;
Capecitabine (Xeloda); Uracil/Tegafur;
Irofulven;
Satraplatin; Gefitinib(Iressa);
Chlorambucil and lomustine;
JM-216;
Cyclophosphamide (C), Etoposide (E), Estramustine (E);
Dexamethasone, Calcitriol, Carboplatin; Epirubicin and filgrastim (g-csf);
Oral cyclophosphamide. 19 March 2005.
Page created 3/19/2006 (H.Hansen)
|
